Last updated: March 7, 2026
What is NDC 00378-4162?
NDC 00378-4162 refers to a specific drug product identified by the National Drug Code (NDC). The NDC 00378-4162 typically corresponds to a branded or generic medication. Precise details of its composition, manufacturer, and approved indications are available from the FDA database and commercial sources.
Based on available data, this NDC represents Doxorubicin Hydrochloride (brand or generic), an anthracycline used primarily for chemotherapy in various cancers, including breast cancer and lymphoma.
What is the current market size for this drug?
Market Size Overview
The chemotherapy drug segment, particularly anthracyclines like doxorubicin, is highly established with steady demand.
| Parameter |
Details |
| Global oncology market (2022) |
$161 billion, expected growth at 7% CAGR through 2027[1] |
| Doxorubicin market share |
Estimated at 15–20% of chemotherapy treatments for breast and lymphoma cancers[2] |
| U.S. oncology drug sales (2022) |
$55 billion, with doxorubicin products accounting for approx. 10% of chemo sales[3] |
Key Drivers
- Incidence of breast cancer: 1.9 million new cases globally in 2022[4].
- Use in lymphoma and other hematological malignancies.
- Established treatment protocols support steady demand.
What are the competitive dynamics?
Major Manufacturers
- Pfizer (e.g., Adriamycin)
- Teva Pharmaceuticals
- Sandoz (Novartis)
- Hospira (Pfizer)
Patent and Regulatory Status
Doxorubicin formulations are largely off patent or have limited patent protection due to patent expirations in the last decade, contributing to a highly competitive generics market.
Market Entry Barriers
- High manufacturing costs related to cytotoxic compound handling.
- Strict regulatory standards for biosafety and quality.
- Presence of established branded and generic products.
How are pricing trends evolving?
Historical Price Trends
| Year |
Average Wholesale Price (AWP) per 10 mg vial |
Source |
| 2018 |
$250 |
Redbook[5] |
| 2020 |
$230 |
IQVIA pricing data[6] |
| 2022 |
$215 |
Medispan[7] |
Prices have declined marginally due to increased generic competition and market saturation.
Current Pricing Range
- Brand (Adriamycin): $200–$250 per 10 mg vial.
- Generic formulations: $140–$180 per 10 mg vial.
Price Projections (2023–2027)
| Year |
Estimated Price Range (per 10 mg vial) |
Assumptions |
| 2023 |
$140–$180 |
Continued competition, patent expirations pressures |
| 2024 |
$130–$170 |
Entry of biosimilars, price negotiations |
| 2025 |
$125–$165 |
Increased biosimilar adoption |
| 2026 |
$120–$160 |
Market saturation, cost containment |
| 2027 |
$115–$155 |
Potential further biosimilar competition |
What are future growth prospects?
Potential Growth Drivers
- Expansion into emerging markets with increasing cancer incidence.
- Adoption of biosimilars and generics reducing costs.
- New clinical indications or combination regimens.
- Shift toward targeted therapies to replace traditional chemotherapies may marginally impact demand but likely keep generics relevant for established protocols.
Risks
- Price erosion due to biosimilar approvals.
- Market shifts favoring newer agents with better safety profiles.
- Competitive pressures from alternative chemotherapies and targeted agents.
Regulatory landscape impact
- The FDA approved biosimilars for doxorubicin, accelerating generic penetration.
- States and payers increasingly favor cost-effective treatments.
- Potential for policy changes impacting drug reimbursement.
Summary
The market for NDC 00378-4162, predominantly representing doxorubicin, remains sizable but faces downward price pressure due to expired patents and biosimilar competition. Current prices suggest a declining trend, with a projected reduction of 20–30% through 2027. The demand remains stable due to established clinical use, though future growth is contingent on market acceptance of biosimilars and emerging therapies.
Key Takeaways
- The global oncology market underpins demand, with steady use of doxorubicin.
- Prices declined from approximately $250 to $215 per 10 mg vial over recent years; further decreases expected.
- Biosimilar and generic competition significantly influence future pricing trajectories.
- Market growth is driven by increasing cancer incidence and expanding global access.
- Regulatory and policy shifts favor cost-effective treatments, pressuring prices downward.
FAQs
1. What are the main competitors to NDC 00378-4162?
Generic formulations from Teva, Sandoz, Hospira, and branded products like Pfizer's Adriamycin are primary competitors.
2. How will biosimilar entry affect prices?
Biosimilars are expected to reduce prices by 20–30%, increasing market share and pressuring traditional formulations.
3. Are there new clinical developments impacting this drug’s demand?
Emerging targeted therapies and immunotherapies may alter chemotherapy's role, but doxorubicin remains a standard option for many indications.
4. What is the outlook for price stabilization?
Prices are likely to continue declining gradually with sustained generic competition and biosimilar adoption.
5. How do regulatory changes influence the market?
FDA approvals of biosimilars and policies favoring cost containment accelerate generic entry and price reduction.
References
[1] Market Research Future. (2022). Oncology Drugs Market Size, Share & Trends.
[2] IQVIA. (2022). Oncology Market Dynamics.
[3] Medispan. (2022). Oncology Drug Pricing Report.
[4] WHO. (2022). Cancer Incidence and Mortality Data.
[5] Redbook. (2018). Wholesale Prices of Oncology Drugs.
[6] IQVIA. (2020). Pharmacoeconomic Data & Trends.
[7] Medispan. (2022). Current Drug Pricing.
